LBL-061

N/A

Report date: 2026/03/20 20:03:07

Base Information

Drug NameLBL-061
Drug Alias NameLBL-061LBL061
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > T cell engagers
Mechanisms of ActionEpidermal growth factor receptor erbB1 modulatorsProgrammed death-ligand 1 modulators
TargetsEpidermal growth factor receptor erbB1Programmed death-ligand 1
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungNasopharyngeal CarcinomaSquamous Cell Carcinoma of Head and Neck
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusIND
Highest Status in ChinaIND
Originator CompaniesNanjing Leadsbiolabs Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNanjing Leadsbiolabs Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungNasopharyngeal CarcinomaSquamous Cell Carcinoma of Head and Neck
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A